FDA clears Misonix's 3-in-1 ultrasonic surgery system

FDA Building
Misonix plans to begin commercialization in July and hopes the Nexus system will serve as a base for future solutions and add-ons. (FDA)

Ultrasonic surgical tool manufacturer Misonix has received clearance from the FDA for its new Nexus system, which combines the features of the company’s three existing handheld offerings into one platform.

That includes BoneScalpel, a precision, oscillating tool designed for millimeter-wide cuts in bone while sparing the surrounding soft tissue. Meanwhile, its SonicOne attachment provides a debridement tool for cleaning wounds and removing damaged tissue or bacterial biofilms during surgery.

The SonaStar ultrasonic aspirator is used to remove more-targeted tissues, such as tumors. It also includes bone-sculpting tips and a range of deep-access and laparoscopic probes.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Farmingdale, New York-based Misonix plans to begin its U.S. commercialization of the combined Nexus platform in July and hopes it will serve as a base for future solutions. It also includes increased power, a touchscreen display and RF capabilities for use in general surgery procedures.

RELATED: TransEnterix granted CE mark for ultrasonic robotic surgery tech

“Nexus is a key component of our strategy to increase our presence in the neuro, spine, ortho, wound and general surgery markets,” Misonix President and CEO Stavros Vizirgianakis said in a statement.

“Nexus provides us with a unique opportunity to leverage our robust consignment business model, further drive the sale of consumables competitively, and extend our ability to cross-sell into multiple physician specialties,” Vizirgianakis added.

Suggested Articles

The company, which was co-founded by Jim Mellon, has reeled in $165 million in 18 months to establish itself at the forefront of the longevity field.

The FDA broadened its approval of Medtronic’s transcatheter aortic valve replacement to include patients at a low risk of surgical complications.

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.